Sweetwater Private Equity
  • About
  • Portfolio
  • Strategy
  • Team
  • News
  • LP Portal
  • Contact
Select Page

Sweetwater Private Equity Recognizes Adam Goldenberg for Leadership and Innovation at upcoming Annual Meeting

by Jad Duncan | Feb 24, 2022 | News

SAN DIEGO, Feb. 24, 2022 /PRNewswire/ — Sweetwater Private Equity (“Sweetwater”) is holding its third annual investor meeting later today at Torrey Pines Lodge where it plans to announce Adam Goldenberg, Co-Founder & CEO of Fabletics, as the 2021...

Apeel Adds $250M to Accelerate Innovation and Sustainability in Fresh Food Supply Chains

by Jad Duncan | Apr 18, 2021 | News

– With demand for fresh, sustainable food on the rise, Apeel’s latest round of funding will speed up the availability of longer-lasting produce in U.S., U.K., and Europe – Apeel-protected produce maintains quality and freshness for much longer,...

Sweetwater Private Equity Closes Oversubscribed First-Time Fund At $350 Million Hard Cap During COVID-19 Crisis

by Jad Duncan | Oct 6, 2020 | News

SAN DIEGO, Oct. 6, 2020 /PRNewswire/ — Sweetwater Investment Management (“Sweetwater” or “Sweetwater Private Equity” (dba)) recently held a final close on its debut multi-client fund, Sweetwater Secondaries Fund II L.P....

WSJ – Sweetwater Collects $350 Million for First Independent Secondary Fund

by Jad Duncan | Sep 30, 2020 | News

The firm collected roughly half of its fund after the onset of the COVID-19 pandemic in March by Laura Cooper Sept. 30, 2020 Sweetwater Investment Management has collected $350 million for its first independent secondary fund, defying a challenging fundraising...

Sweetwater Private Equity recognizes Adaptive Biotechnologies Corp. and its CEO Chad Robins for leadership during COVID-19 crisis

by Jad Duncan | Apr 28, 2020 | News

SAN DIEGO, April 28, 2020 /PRNewswire/ — Sweetwater Investment Management (“Sweetwater” or “Sweetwater Private Equity” (dba)) announced during their recent annual investor meeting the selection of Chad Robins, CEO of Adaptive...
  • LinkedIn
  • Twitter

Designed by Elegant Themes | Powered by Powered by WordPress.com.

Legal Notice & Terms of Use | Privacy Policy | Investor Portal | Proudly powered by WordPress.